

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23K 1/165		A1	(11) International Publication Number: WO 98/54982 (43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: PCT/US98/11347		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 June 1998 (03.06.98)			
(30) Priority Data: 60/048,452 3 June 1997 (03.06.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/048,452 (CIP) Filed on 3 June 1997 (03.06.97)			
(71) Applicant (for all designated States except US): GANESEN BIOTECH, INC. [US/US]; 8738-6 Villa La Jolla Drive, La Jolla, CA 92037 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): FARMER, Sean [US/US]; 8738-6 Villa La Jolla Drive, La Jolla, CA 92037 (US). MIKHAIL, Robert, J. [US/US]; 1493-B E. Lexington Avenue, El Cajon, CA 92019 (US).			
(74) Agent: FITTING, Thomas; Suite 300, 12526 High Bluff Drive, San Diego, CA 92130 (US).			

(54) Title: PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS

(57) Abstract

Compositions including a non-pathogenic lactic acid-producing bacteria, such as a *Bacillus* species, spores or an extracellular product of *B. coagulans*, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome (SIDS) are also disclosed.